
Eve-Isabelle Pécheur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6517644/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Heparanase-1 is upregulated by hepatitis C virus and favors its replication. Journal of Hepatology, 2022, 77, 29-41.	1.8	6
2	HCV Virology. , 2021, , 1-44.		0
3	Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis. Cancers, 2021, 13, 2270.	1.7	6
4	Circulating micro-RNAs as biomarkers of liver fibrosis progression in hepatitis C virus/HIV-1-co-infected patients: a â€~miR'-velous opportunity of early diagnosis?. Aids, 2021, 35, 1499-1500.	1.0	0
5	Impact of Gold Nanoparticles on the Functions of Macrophages and Dendritic Cells. Cells, 2021, 10, 96.	1.8	22
6	Altered BMP2/4 Signaling in Stem Cells and Their Niche: Different Cancers but Similar Mechanisms, the Example of Myeloid Leukemia and Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 787989.	1.8	6
7	First description of a compensatory xylosyltransferase I induction observed after an antifibrotic UDP-treatment of normal human dermal fibroblasts. Biochemical and Biophysical Research Communications, 2019, 512, 7-13.	1.0	4
8	Innovative particle standards and long-lived imaging for 2D and 3D dSTORM. Scientific Reports, 2019, 9, 17967.	1.6	9
9	Hepatitis C virus infection propagates through interactions between Syndecan-1 and CD81 and impacts the hepatocyte glycocalyx. Cellular Microbiology, 2017, 19, e12711.	1.1	31
10	The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. Journal of Virology, 2016, 90, 3086-3092.	1.5	133
11	Virus Optical Imaging: Far-Red Fluorescent Lipid-Polymer Probes for an Efficient Labeling of Enveloped Viruses (Adv. Healthcare Mater. 16/2016). Advanced Healthcare Materials, 2016, 5, 2031-2031.	3.9	1
12	Farâ€Red Fluorescent Lipidâ€Polymer Probes for an Efficient Labeling of Enveloped Viruses. Advanced Healthcare Materials, 2016, 5, 2032-2044.	3.9	7
13	Glutathione peroxidase 4 is reversibly induced by HCV to control lipid peroxidation and to increase virion infectivity. Gut, 2016, 65, 144-154.	6.1	45
14	Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion. Journal of Virology, 2015, 89, 10333-10346.	1.5	59
15	Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution. Journal of Virology, 2014, 88, 667-678.	1.5	2
16	In vitro infection of primary human hepatocytes by HCV-positive sera: insights on a highly relevant model. Gut, 2014, 63, 1490-1500.	6.1	19
17	Curcumin against hepatitis C virus infection: spicing up antiviral therapies with â€~nutraceuticals'?. Gut, 2014, 63, 1035-1037.	6.1	15
18	Arbidol as a broad-spectrum antiviral: An update. Antiviral Research, 2014, 107, 84-94.	1.9	375

#	Article	IF	CITATIONS
19	Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus. Antiviral Research, 2014, 109, 141-148.	1.9	16
20	Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antiviral Research, 2013, 100, 215-219.	1.9	72
21	Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cellular Microbiology, 2013, 15, n/a-n/a.	1.1	73
22	Lipids ‒ A key for hepatitis C virus entry and a potential target for antiviral strategies. Biochimie, 2013, 95, 96-102.	1.3	31
23	Phenothiazines Inhibit Hepatitis C Virus Entry, Likely by Increasing the Fluidity of Cholesterol-Rich Membranes. Antimicrobial Agents and Chemotherapy, 2013, 57, 2571-2581.	1.4	48
24	Very-Low-Density Lipoprotein (VLDL)-Producing and Hepatitis C Virus-Replicating HepG2 Cells Secrete No More Lipoviroparticles than VLDL-Deficient Huh7.5 Cells. Journal of Virology, 2013, 87, 5065-5080.	1.5	34
25	Silymarin for HCV infection. Antiviral Therapy, 2013, 18, 141-147.	0.6	55
26	Lipoprotein Receptors and Lipid Enzymes in Hepatitis C Virus Entry and Early Steps of Infection. Scientifica, 2012, 2012, 1-11.	0.6	8
27	Targeting Cell Entry of Enveloped Viruses as an Antiviral Strategy. Molecules, 2011, 16, 221-250.	1.7	80
28	Differential In Vitro Effects of Intravenous versus Oral Formulations of Silibinin on the HCV Life Cycle and Inflammation. PLoS ONE, 2011, 6, e16464.	1.1	62
29	Identification of a Functional, CRM-1-Dependent Nuclear Export Signal in Hepatitis C Virus Core Protein. PLoS ONE, 2011, 6, e25854.	1.1	28
30	Benzophenone-containing fatty acids and their related photosensitive fluorescent new probes: Design, physico-chemical properties and preliminary functional investigations. Bioorganic and Medicinal Chemistry, 2011, 19, 7464-7473.	1.4	5
31	Mechanism of Inhibition of Enveloped Virus Membrane Fusion by the Antiviral Drug Arbidol. PLoS ONE, 2011, 6, e15874.	1.1	106
32	Lipoprotein Lipase Inhibits Hepatitis C Virus (HCV) Infection by Blocking Virus Cell Entry. PLoS ONE, 2011, 6, e26637.	1.1	48
33	Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology, 2010, 51, 1912-1921.	3.6	191
34	Morphological Characterization and Fusion Properties of Triglyceride-rich Lipoproteins Obtained from Cells Transduced with Hepatitis C Virus Glycoproteins. Journal of Biological Chemistry, 2010, 285, 25802-25811.	1.6	13
35	Characterization of hepatitis C virus pseudoparticles by cryo-transmission electron microscopy using functionalized magnetic nanobeads. Journal of General Virology, 2010, 91, 1919-1930.	1.3	26
36	Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes. Journal of Virology, 2010, 84, 5751-5763.	1.5	201

Eve-Isabelle Pécheur

#	Article	IF	CITATIONS
37	Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles. Journal of Biological Chemistry, 2009, 284, 17657-17667.	1.6	79
38	Characterization of Lassa Virus Cell Entry and Neutralization with Lassa Virus Pseudoparticles. Journal of Virology, 2009, 83, 3228-3237.	1.5	51
39	The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership. Biochemical Journal, 2009, 423, 303-314.	1.7	39
40	The Exchangeable Apolipoprotein ApoC-I Promotes Membrane Fusion of Hepatitis C Virus. Journal of Biological Chemistry, 2007, 282, 32357-32369.	1.6	80
41	Transmembrane Domains of Hepatitis C Virus Envelope Glycoproteins: Residues Involved in E1E2 Heterodimerization and Involvement of These Domains in Virus Entry. Journal of Virology, 2007, 81, 2372-2381.	1.5	76
42	Characterization of Fusion Determinants Points to the Involvement of Three Discrete Regions of Both E1 and E2 Glycoproteins in the Membrane Fusion Process of Hepatitis C Virus. Journal of Virology, 2007, 81, 8752-8765.	1.5	157
43	Biochemical Mechanism of Hepatitis C Virus Inhibition by the Broad-Spectrum Antiviral Arbidol. Biochemistry, 2007, 46, 6050-6059.	1.2	80
44	Lipids as modulators of membrane fusion mediated by viral fusion proteins. European Biophysics Journal, 2007, 36, 887-899.	1.2	97
45	Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virology Journal, 2006, 3, 56.	1.4	77
46	Hepatitis C Virus Glycoproteins Mediate Low pH-dependent Membrane Fusion with Liposomes. Journal of Biological Chemistry, 2006, 281, 3909-3917.	1.6	119
47	Anchorage of Synthetic Peptides onto Liposomes via Hydrazone and α-Oxo Hydrazone Bonds. Preliminary Functional Investigations. Bioconjugate Chemistry, 2005, 16, 450-457.	1.8	39
48	Peptide-Induced Fusion of Liposomes. , 2002, 199, 31-48.		4
49	Protein-induced Fusion Can Be Modulated by Target Membrane Lipids through a Structural Switch at the Level of the Fusion Peptide. Journal of Biological Chemistry, 2000, 275, 3936-3942.	1.6	34
50	Lipid Headgroup Spacing and Peptide Penetration, but Not Peptide Oligomerization, Modulate Peptide-Induced Fusionâ€. Biochemistry, 1999, 38, 364-373.	1.2	29
51	Membrane Fusion Induced by 11-mer Anionic and Cationic Peptides: A Structureâ^'Function Studyâ€. Biochemistry, 1998, 37, 2361-2371.	1.2	31